Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab.
García-Cadenas I, Castillo N, Martino R, Barba P, Esquirol A, Novelli S, Orti G, Garrido A, Saavedra S, Moreno C, Granell M, Briones J, Brunet S, Navarro F, Ruiz I, Rabella N, Valcárcel D, Sierra J. García-Cadenas I, et al. Among authors: granell m. Bone Marrow Transplant. 2015 Apr;50(4):579-84. doi: 10.1038/bmt.2014.298. Epub 2015 Jan 12. Bone Marrow Transplant. 2015. PMID: 25581404
Incorporating posttransplant cyclophosphamide-based prophylaxis as standard-of-care outside the haploidentical setting: challenges and review of the literature.
García-Cadenas I, Awol R, Esquirol A, Saavedra S, Bosch-Vilaseca A, Novelli S, Garrido A, López J, Granell M, Moreno C, Briones J, Brunet S, Sierra J, Martino R. García-Cadenas I, et al. Among authors: granell m. Bone Marrow Transplant. 2020 Jun;55(6):1041-1049. doi: 10.1038/s41409-019-0771-2. Epub 2019 Dec 10. Bone Marrow Transplant. 2020. PMID: 31822813 Review.
Degree of mucositis and duration of neutropenia are the major risk factors for early post-transplant febrile neutropenia and severe bacterial infections after reduced-intensity conditioning.
Facchini L, Martino R, Ferrari A, Piñana JL, Valcárcel D, Barba P, Granell M, Delgado J, Briones J, Sureda A, Brunet S, Sierra J. Facchini L, et al. Among authors: granell m. Eur J Haematol. 2012 Jan;88(1):46-51. doi: 10.1111/j.1600-0609.2011.01724.x. Eur J Haematol. 2012. PMID: 22023368 Clinical Trial.
Do Patients and Physicians Agree When They Assess Quality of Life?
Barata A, Martino R, Gich I, García-Cadenas I, Abella E, Barba P, Briones J, Brunet S, Esquirol A, García-Pallarols F, Garrido A, Granell M, Martinez J, Mensa I, Novelli S, Sánchez-González B, Valcárcel D, Sierra J. Barata A, et al. Among authors: granell m. Biol Blood Marrow Transplant. 2017 Jun;23(6):1005-1010. doi: 10.1016/j.bbmt.2017.03.015. Epub 2017 Mar 10. Biol Blood Marrow Transplant. 2017. PMID: 28288950 Free article.
Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial.
Rosiñol L, Oriol A, Teruel AI, de la Guía AL, Blanchard M, de la Rubia J, Granell M, Sampol M, Palomera L, González Y, Etxebeste M, Martínez-Martínez R, Hernández MT, de Arriba F, Alegre A, Cibeira M, Mateos M, Martínez-López J, Lahuerta JJ, San Miguel J, Bladé J. Rosiñol L, et al. Among authors: granell m. Leukemia. 2017 Sep;31(9):1922-1927. doi: 10.1038/leu.2017.35. Epub 2017 Jan 23. Leukemia. 2017. PMID: 28111466 Clinical Trial.
Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group.
Mosquera Orgueira A, González Pérez MS, Diaz Arias J, Rosiñol L, Oriol A, Teruel AI, Martinez Lopez J, Palomera L, Granell M, Blanchard MJ, de la Rubia J, López de la Guia A, Rios R, Sureda A, Hernandez MT, Bengoechea E, Calasanz MJ, Gutierrez N, Martin ML, Blade J, Lahuerta JJ, San Miguel J, Mateos MV; PETHEMA/GEM Cooperative Group. Mosquera Orgueira A, et al. Among authors: granell m. Blood Cancer J. 2022 Apr 25;12(4):76. doi: 10.1038/s41408-022-00647-z. Blood Cancer J. 2022. PMID: 35468898 Free PMC article.
A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control.
Paiva B, Vídriales MB, Rosiñol L, Martínez-López J, Mateos MV, Ocio EM, Montalbán MÁ, Cordón L, Gutiérrez NC, Corchete L, Oriol A, Terol MJ, Echeveste MA, De Paz R, De Arriba F, Palomera L, de la Rubia J, Díaz-Mediavilla J, Granell M, Gorosquieta A, Alegre A, Orfao A, Lahuerta JJ, Bladé J, San Miguel JF; Grupo Español de MM/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group. Paiva B, et al. Among authors: granell m. Leukemia. 2013 Oct;27(10):2056-61. doi: 10.1038/leu.2013.166. Epub 2013 Jun 7. Leukemia. 2013. PMID: 23743858
Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial.
Bahlis NJ, Corso A, Mugge LO, Shen ZX, Desjardins P, Stoppa AM, Decaux O, de Revel T, Granell M, Marit G, Nahi H, Demuynck H, Huang SY, Basu S, Guthrie TH, Ervin-Haynes A, Marek J, Chen G, Facon T. Bahlis NJ, et al. Among authors: granell m. Leukemia. 2017 Nov;31(11):2435-2442. doi: 10.1038/leu.2017.111. Epub 2017 Apr 4. Leukemia. 2017. PMID: 28373701 Free PMC article. Clinical Trial.
114 results